Conscio Group, a pharmaceutical company, agreed to acquire Gen-Plus, an R&D and manufacturing company. Financial terms were not disclosed. “Gen-Plus offers unique technology and innovation capabilities through its extensive project experience. The continuous investment into new capabilities enables Gen-Plus to develop better medication for patients. The Company’s relentless focus on its customers, agile working mode, and scientific work of the highest quality has impressed us and is aligned with Conscio Group’s own values. We look forward to partnering with Dr. Dachtler and the entire Gen-Plus team to grow and develop the organization,“ Wolfhart Hauser, Conscio Group Chairman.